THE IMPACT OF DISEASE-MODIFYING MEDICATIONS ON THE LIPID PROFILE OF PATIENTS WITH ISCHEMIC HEART DISEASE.

Background: Ischemic heart diseases (IHD) refer to narrowing of coronary artery resulting in partial or complete stenosis making patients susceptible to myocardial infarction (MI) and stroke challenging the healthcare provider due to high risk of morbidity and mortality. The aim of this study was directed to identify the role various disease-modifying medications (DMMs) in the treatment of IHD-associated risk factors, including statins, sodium-glucose transporter (SGLT2) inhibitors, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Methods: A total of 500 patients recruited from multicentre were enrolled in this randomized controlled clinical trial. The patients were subdivided into 4-treatment groups, including statin group, SGLT-2 inhibitors group, PCSK9 inhibitors group, or combination therapy group. The serum lipid parameters were measured initially and after 12 months post-therapy.

Results: The treatment groups have demonstrated reduction of lipid parameters at the end of the 12-months of study period. The combination therapy has provided the greatest reduction (-74±10 mg/dL, p<0.05). Age and gender has slightly modulated the response to these medications.

Conclusion: The combination of DMMs carry may be a valuable tool for managing the lipid parameters reducing risk factors that prone IHD-patients to stroke and MI, suggesting additional therapeutic role for cardiovascular disease managements.